<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365804">
  <stage>Registered</stage>
  <submitdate>21/03/2014</submitdate>
  <approvaldate>10/04/2014</approvaldate>
  <actrnumber>ACTRN12614000390684</actrnumber>
  <trial_identification>
    <studytitle>Fish oil in chronic psychiatric outpatients with anxiety and mood disorders.</studytitle>
    <scientifictitle>Adjunctive natural low dose docosahexaenoic acid (DHA) omega-3 in a 16 week random double-blind placebo controlled (RDBPC) cross-over withdrawal study in a group of chronic, psychiatric out-patients with anxiety and mood disorders. </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic anxiety and mood disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Natural low dose docosahexaenoic acid (DHA) omega-3
(NeuroSpark) 130-390mg per day in addition to standard psychiatric treatments.

The dose in the study is the dose which has been found clinically to be appropriate and efficacious for each individual entering the study. 
 
Oral.  

This study medication will be administered for 16 weeks (24 week study minus 8 weeks on placebo = 16 weeks of study medication). 

There is no washout period. 

Adherence to study medication regimen will be monitored via capsule return and self-report daily diary entries.</interventions>
    <comparator>Placebo - safflower oil capsules. </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measure the effectiveness of the DHA omega-3 versus placebo on neurocognitive and psychiatric symptoms.

This will be measured by the following scales: Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HAM-D), Leeds Sleep Evaluation, Fatigue questionnaire. 

In addition, patients will complete the following scales: Depression, Anxiety and Stress Scale (DASS), Visual Analogue tracking of short-term memory, concentration, clarity of thinking, anxiety, mood swings/irritability, energy depression and sleep.  </outcome>
      <timepoint>At the conclusion of the study (at 24 weeks).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in cognitive function using COMPASS cognitive testing in the areas of attention, immediate recall, spatial working memory and executive functioning. </outcome>
      <timepoint>At each study visit, at weeks 0, 4, 12, 20 and 24. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Levels of metabolites of Arachidonic acid (AA); cytokines (e.g. TNF-alpha and others), inflammatory markers (CRP), erythrocyte membrane polyunsaturated fatty acid (PUFA) analyses to measure PUFA levels. 
</outcome>
      <timepoint>Weeks 4, 12, 20.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Outpatients with chronic anxiety and/or depressive symptoms. 
2. Patients currently taking DHA (NeuroSpark) capsules for at least 3 months prior to study entry. 
 
</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. ADHD
2. Brain injury
3. Mild cognitive impairment
4. Dementias
5. Substance dependence and/or abuse
6. Schizophrenia
7. Acutely suicidal patients
8. Chronic unstable medical conditions</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Following the open label phase (first 4 weeks of the study) there will be 2 double-blind crossover phases, each of 8 weeks duration, where the participant will first take DHA omega-3 then lookalike placebo capsule containing safflower oil, or placebo then DHA omega-3. In the final 4 weeks phase all participants receive DHA omega-3.
 
The procedure used for allocating the treatment will be by numbered containers. </concealment>
    <sequence>Methods used to generate the sequence for randomisation will be done by simple randomisation, using a randomisation table from a statistic book. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>This is a small scale pilot study in a clinical setting. 
The study results will be analysed by mixed models repeated measures analysis of variance (ANOVA). </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>5/02/2016</anticipatedenddate>
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Enrolling by invitation</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3123 - Hawthorn East</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michael Piperoglou</primarysponsorname>
    <primarysponsoraddress>Private Consulting Rooms, 790 Burwood Road, Hawthorn East VIC 3123</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate the effectiveness of the adjunctive role of DHA omega-3 in outpatients with chronic anxiety and depression. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Melbourne Clinic Research Ethics Committee</ethicname>
      <ethicaddress>130 Church Street, Richmond VIC 3121</ethicaddress>
      <ethicapprovaldate>11/12/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Michael Piperoglou</name>
      <address>Private practitioner in specialist psychiatric practice at 790 Burwood Road, Hawthorn East VIC 3123

Masters student at University of Melbourne, Dept of Psychiatry</address>
      <phone>+61 3 9813 1144</phone>
      <fax>+61 3 9882 0866</fax>
      <email>micpip@bigpond.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Piperoglou</name>
      <address>Private practitioner in specialist psychiatric practice at 790 Burwood Road, Hawthorn East VIC 3123

Masters student at University of Melbourne, Dept of Psychiatry</address>
      <phone>+61 3 9813 1144</phone>
      <fax />
      <email>micpip@bigpond.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Piperoglou</name>
      <address>Private practitioner in specialist psychiatric practice at 790 Burwood Road, Hawthorn East VIC 3123

Masters student at University of Melbourne, Dept of Psychiatry</address>
      <phone>+61 3 9813 1144</phone>
      <fax />
      <email>micpip@bigpond.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Iveta Krivonos</name>
      <address>31 Albert Road
Melbourne VIC 3004</address>
      <phone>+61 3 9256 8331 </phone>
      <fax />
      <email>ivetak@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>